

Received: 2008.10.13  
 Accepted: 2009.01.15  
 Published: 2009.03.16

## The effect of *CYP3A5* and *ABCB1* single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients

Alessio Provenzani<sup>1</sup>, Monica Notarbartolo<sup>2</sup>, Manuela Labbozzetta<sup>2</sup>, Paola Poma<sup>2</sup>, Filippo Biondi<sup>2</sup>, Rosario Sanguedolce<sup>2</sup>, Giovanni Vizzini<sup>3</sup>, Ugo Palazzo<sup>4</sup>, Piera Polidori<sup>1</sup>, Fabio Triolo<sup>5</sup>, Bruno Gridelli<sup>6</sup>, Natale D'Alessandro<sup>2</sup>

<sup>1</sup> Department of Clinical Pharmacy, ISMETT, Palermo, Italy

<sup>2</sup> Department of Pharmacological Sciences "Pietro Benigno", University of Palermo, Italy

<sup>3</sup> Department of Medicine, ISMETT, Palermo, Italy

<sup>4</sup> Health Direction, ISMETT, Palermo, Italy

<sup>5</sup> Regenerative Medicine and Cell Therapy Unit, ISMETT, Palermo, Italy

<sup>6</sup> Department of Abdominal Surgery and Transplantation, ISMETT, Palermo, Italy

This work was presented at the International Conference 'Therapeutic Drug Monitoring in Optimizing the Immunosuppressive Therapy', Warsaw, Poland, 26<sup>th</sup>-27<sup>th</sup> September 2008

**Source of support:** This study was supported by ISMETT and by Dottorato di Ricerca in Farmacologia e Tossicologia Socio-Ambientale, University of Palermo

### Summary

#### Background:

Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the drug transporter *ABCB1*. We have investigated the effects of possible relevant *CYP3A5* and *ABCB1* single nucleotide polymorphisms (SNPs) present in both donors and recipients on tacrolimus blood levels achieved in a population of 32 Caucasian liver transplant patients.

#### Material/Methods:

At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels ( $C_0$ ) were determined. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping *CYP3A5*\*3 [6986A>G] as well as *ABCB1* at exons 21 [2677G>T] and 26 [3435C>T].

#### Results:

87.5% of the population showed a *CYP3A5*\*3/\*3 genotype. For the *ABCB1* SNPs, in the case of 3435C>T the total frequency observed for the allelic variant was 50%. For the 2677G>T, the total frequency of the allelic variant was 12.5%, lower than in other Caucasian populations and without any significant linkage with 3435C>T. At 3 and 6 months after transplantation, tacrolimus dose requirements were significantly higher in patients receiving a liver with one copy of the \*1 allele compared to those homozygous for the \*3 allele ( $0.111 \pm 0.057$  vs.  $0.057 \pm 0.030$  [ $P < 0.05$ ] at 3 month and  $0.086 \pm 0.051$  vs.  $0.044 \pm 0.025$  [ $P < 0.05$ ] at 6 month). For the recipients' genotypes, the presence of at least one \*1 copy tended, though not statistically significantly, to increase tacrolimus doses. With regard to the *ABCB1* SNPs, they did not show any influence on tacrolimus dosing requirements.

#### Conclusions:

Pharmacogenetic analysis of *CYP3A5* in the donor could contribute to determine the appropriate initial dosage of tacrolimus in liver transplant patients.

---

**Key words** tacrolimus • single nucleotide polymorphisms • *CYP3A5* • *ABCB1* • liver transplant

---

**Full-text PDF:** <http://www.annalsoftransplantation.com/fulltxt.php?ICID=880644>**Word count:** 4447**Tables:** 2**Figures:** –**References:** 62**Author's address:** Alessio Provenzani, Department of Clinical Pharmacy, ISMETT, Via E. Tricomi n. 1, 90127 Palermo, Italy, e-mail: aprovenzani@ismett.edu

---

**BACKGROUND**

---

Tacrolimus is an immunosuppressant widely used in liver transplant patients. Due to its narrow therapeutic index and high inter- and intra-individual pharmacokinetic variability, the administration regimens of this drug need to be closely monitored [1]. In fact, achieving the desired target blood concentrations immediately after transplantation is of critical importance to avoid rejection or excessive immunosuppression and to limit important dose-related adverse reactions such as nephrotoxicity, neurotoxicity and hyperglycemia [1].

To date the most widely used parameter for the therapeutic monitoring of tacrolimus is its trough whole blood concentration ( $C_0$ ), that is measured 12 hours after the dose administration and correlates well with the area under the concentration-time curve [2,3].

Many factors of pharmacokinetic and pharmacodynamic nature may influence the activity of the drug [1,2,4,5]. Also the genetic background may influence the inter-individual variability in the pharmacokinetics of tacrolimus [6].

After oral administration, tacrolimus has limited bioavailability (~25%, but it can vary from 4% to 93%) and is extensively metabolized by the oxidative enzymes cytochromes P4503A (*CYP3A4* and *CYP3A5*) in the intestinal wall and liver [1,7]. *CYP3A* constitute the most abundant group of the cytochrome P450 family and are responsible for the metabolism of more than half of clinically used drugs [8,9]. Previous studies have shown that a single nucleotide polymorphism (SNP), that is 6986A>G at intron 3, correlates with *CYP3A5* protein production and enzyme activity [10]. Individuals with at least one wild-type allele (\*1) express hepatic and intestinal *CYP3A5*, whereas the subjects homozygous for

the mutant variant (\*3/\*3) do not present a functional protein [10,11]. Accordingly, several studies have indicated that this *CYP3A5* SNP can be associated with changes in tacrolimus dose requirements [12–14].

In addition, similarly to other drugs commonly used in transplantation, tacrolimus is also a substrate of P-glycoprotein (P-gp), a membrane drug efflux transporter encoded by the multi-drug resistance *ABCB1* (*MDR1*) gene [15]. P-gp is present in several human tissues and organs like the intestine, adrenal gland, kidney, liver, blood-brain barrier, placenta, lymphocytes, ovary and testis [16]. It influences the disposition of several xenobiotics by limiting their absorption from the gut lumen and increasing their biliary and urinary excretion [17,18].

It has been suggested that some SNPs of the *ABCB1* gene, like 2677G>T at exon 21 and 3435C>T at exon 26, may cause altered P-gp expression and function [19,20]. Although 3435C>T is a silent polymorphism, that does not result in an amino acid change in the encoded protein, it may be in linkage disequilibrium with other functional polymorphisms of the *ABCB1* gene, including 2677G>T, which causes a serine-alanine substitution and results in a low expression of intestinal P-gp [21]. In addition, recent data have suggested that the 3435C>T substitution may reduce *ABCB1* mRNA stability in the liver [22]. People with the 2677GG or 3435CC genotypes would have greater function of the drug transporter associated with lower tacrolimus bioavailability and level/dose ratios [21,23,24]. However, the conclusions drawn so far on the real importance of *ABCB1* SNPs on tacrolimus or cyclosporine pharmacokinetics are largely controversial [14,21,23–26].

Importantly, the allele frequencies of the aforementioned *CYP3A5* and *ABCB1* SNPs can widely differ among ethnic groups [27–29]. The objec-

tive of this exploratory study was to analyze the possible influence of these SNPs on tacrolimus dose requirements in a population of Caucasian, mainly Sicilian, liver transplant patients.

## MATERIAL AND METHODS

### Subjects

A total of 32 subjects (24 males, 8 females) who underwent liver transplantation at the Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT) and their respective donors were consecutively included in this study. The average age of the liver transplant recipients was  $53.53 \pm 12.38$  (15–66) years; all them were Caucasians and in particular 29 (90.6%) were Sicilians. The average age of the transplant donors was  $39.25 \pm 18.99$  (15–82); 13 were males and 19 females and all Caucasians (65.6% Sicilians). After transplantation, the recipients were treated with tacrolimus, alone or in combination with steroids (mostly during the first month) and/or mycophenolate mofetil.

They were checked to make sure that they were not taking any drug known to interact with tacrolimus. The average initial tacrolimus dose was 0.015 mg/kg every 12 hours subsequently adjusted according to the whole blood trough ( $C_0$ ) levels. The target  $C_0$  level was set between 5 and 12 ng/mL.

Body weight, laboratory data (including albumin, serum creatinine and liver function tests), tacrolimus dosage (mg/kg/day) and  $C_0$  levels were recorded at 1, 3 and 6 months after transplantation. Blood samples for tacrolimus  $C_0$  levels determinations were drawn just prior to the morning dose. Whole blood tacrolimus concentrations were measured by EMIT 2000 immunoassay (DADE Behring, Hilden, Germany). The dose-adjusted  $C_0$  level (L/D) was calculated by dividing the tacrolimus  $C_0$  level by the corresponding 24 h dose. The information thus obtained was the tacrolimus dose needed to obtain a given  $C_0$  level.

The protocol was approved by the Institutional Review Board of ISMETT and informed consent was obtained for all patients.

### Genotype identification

Recipient and donor genotypes were determined by analysing 200  $\mu$ L of EDTA-anticoagulated

blood. Genomic DNA was extracted using the QIAmp DNA Mini Kit (Qiagen, Crawley, UK). The PCR-RFLP (polymerase chain reaction – restriction fragment length polymorphism) assay was then applied to identify the *CYP3A5*\*3, 2677G>T and 3435C>T genetic polymorphisms. We used 150 ng of genomic DNA for PCR amplification.

The forward primer for *CYP3A5*\*3 was 5'-CAT CAG TTA GTA GAC AGA TGA-3' and the reverse primer was 5'-GGT CCA AAC AGG GAA GAA ATA-3'; the forward primer for 2677G>T was 5'-TAC CCA TCA TTG CAA TAG CAG-3' and the reverse primer was 5'-TTT AGT TTG ACT CAC CTT TCT AG-3'; the forward primer for 3435C>T was 5'-CAT GCT CCC AGG CTG TTT AT-3' and the reverse primer was 5'-GTA ACT TGG CAG TTT CAG TG-3'. PCR was performed in a total volume of 50  $\mu$ L with 40 picomoles of each primer, 0.2 mM dNTP, 1 X High Fidelity PCR Buffer (600 mM TRIS-SO<sub>4</sub> pH 8.9 and 180 mM NH<sub>4</sub> SO<sub>4</sub>), 2 mM Mg SO<sub>4</sub> and 1.5 U of Taq DNA polymerase (Platinum Taq High Fidelity, Invitrogen, Carlsbad, CA, USA). PCR process included initial denaturation at 94°C for 7 min, followed by 35 cycles of denaturation for 1 min at 94°C, 35 cycles of annealing for 1 min at 55°C, and 35 cycles of synthesis for 1 min at 72°C. The final extension was carried out for 7 min at 72°C. The PCR products (10  $\mu$ L for each samples) were analyzed by electrophoresis on 1% agarose gel. The enzymatic digestion was performed for 2 hours at 37°C using specific restriction enzymes. For *CYP3A5*\*3 we used 15  $\mu$ L of PCR product and 10 U of SspI plus 1 X Buffer (50 mM NaCl, 100 mM TRIS-HCl, 10 mM MgCl<sub>2</sub> and 0.025% Triton X-100) in a total volume of 20  $\mu$ L; for 2677G>T, we used 15  $\mu$ L of PCR product and 20 U of XbaI plus 1 X Buffer (50 mM NaCl, 10 mM TRIS-HCl, 10 mM MgCl<sub>2</sub> and 1 mM DTT) in a total volume of 20  $\mu$ L; and for 3435C>T we used 10  $\mu$ L of PCR product and 10 U of DpnII plus 1 X Buffer (100 mM NaCl, 50 mM BIS TRIS-HCl, 10 mM MgCl<sub>2</sub> and 1 mM dithiothreitol) in a total volume of 15  $\mu$ L. The digestion products were then subjected to 3% agarose gel electrophoresis and detected by staining with ethidium bromide.

### Statistical analysis

All values were expressed as means  $\pm$  SD and the two-tailed Mann-Whitney U test was employed to determine the difference in continuous values among groups. The  $\chi^2$ -square test was used to analyse differences between Sicilian and non-Sicilian subjects.

**Table 1.** Distribution of *CYP3A5* and *ABCB1* genotypes in liver transplant donors and recipients.

Recipients' genotype	Allelic status	n. of pts	Donors' genotype	Allelic status	n. of pts	Total percentage of expression
CYP 3A5*3	*3/*3	29 (90.7%)	CYP3A5*3	*3/*3	27 (84.4%)	87.5 (56/64)
	*1/*3	2 (6.2%)		*1/*3	5 (15.6%)	10.9 (7/64)
	*1/*1	1 (3.1%)		*1/*1	–	1.6 (1/64)
ABCB1 2677G>T (Exon 21)	G/G	27 (84.4%)	ABCB1 2677G>T (Exon 21)	G/G	23 (71.9%)	78.0 (50/64)
	G/T	5 (15.6%)		G/T	7 (21.9%)	19.0 (12/64)
	T/T	–		T/T	2 (6.2%)	3.0 (2/64)
ABCB1 3435C>T (Exon 26)	C/C	5 (15.6%)	ABCB1 3435C>T (Exon 26)	C/C	10 (31.2%)	23.4 (15/64)
	C/T	19 (59.4%)		C/T	15 (46.8%)	53.2 (34/64)
	T/T	8 (25.0%)		T/T	7 (22.0%)	23.4 (15/64)

The allele and genotype frequencies of the *CYP3A5* and *ABCB1* polymorphisms were assessed for deviation from the Hardy-Weinberg equilibrium using the  $\chi^2$ -square test. P values <0.05 were considered statistically significant.

## RESULTS

### Frequency of *CYP3A5* and *ABCB1* variants in liver transplant recipients and donors

As shown in Table 1, among the 32 liver transplant recipients involved in the study, *CYP3A5*\*3/\*3 genotype was observed in 29 (90.7%) cases, *CYP3A5*\*1/\*3 in 2 (6.2%) cases and *CYP3A5*\*1/\*1 in 1 (3.1%) case. For the corresponding donors, *CYP3A5*\*3/\*3 genotype was present in 27 (84.4%) cases and *CYP3A5*\*1/\*3 in 5 (15.6%) cases. Overall, the frequency of *CYP3A5*\*3/\*3 was 87.5% (56/64 subjects), that of \*1/\*3 10.9% (7/64 subjects) and that of \*1/\*1 1.6% (1/64 subjects). The total allelic frequency was 93% for *CYP3A5*\*3 and 7% for *CYP3A5*\*1.

As for the *ABCB1* SNP at exon 21 (2677G>T), the GG and GT genotypes were found in 27 (84.4%) and 5 (15.6%) of the transplant recipients, respectively. The GG, GT and TT genotypes were found in 23 (71.9%), 7 (21.9%) and 2 (6.2%) of the donors, respectively. The overall percentages of expression of GG, GT and TT were 78.1, 18.8 and 3.1, respectively. The total frequency of the allelic variant was 12.5%.

For the SNP of *ABCB1* at exon 26 (3435C>T), among the recipients, the CC, CT and TT geno-

types were observed in 5 (15.6%), 19 (59.4%) and 8 (25%) cases, respectively. Among the donors, the CC, CT and TT genotypes were observed in 10 (31.2%), 15 (46.8%) and 7 (22%) cases, respectively. The overall percentages of expression were 23.4, 53.2 and 23.4 for the wild-type, heterozygous and homozygous mutated genotypes, respectively. The total frequency observed for the allelic variant was 50%.

The data showed no significant association between the two *ABCB1* polymorphisms. The *CYP3A5* and *ABCB1* genotype frequencies were not significantly different from those predicted by the Hardy-Weinberg equilibrium, thus indicating the reliability of the genotype determinations.

### Relationship of *CYP3A5* and *ABCB1* SNPs to tacrolimus C<sub>0</sub> blood levels and dose requirements

At 1, 3 and 6 months after liver transplant the average tacrolimus doses (mg/kg/day) were 0.083 (0.025–0.157), 0.066 (0.014–0.21) and 0.051 (0.006–0.177), respectively. Table 2 shows the tacrolimus doses needed to obtain a given blood C<sub>0</sub> level according to the donors' and recipients' genotypes. The data (Table 2) show an influence of the donors' genotypes on tacrolimus dose requirements only for the *CYP3A5* gene. In fact, 3 and 6 months after transplantation, the daily doses of tacrolimus needed to reach target blood levels were significantly (P<0.05) higher in the patients receiving a liver with one copy of the \*1 allele compared to those homozygous for

**Table 2.** Relationship between genotypes, blood levels and tacrolimus doses.

	Level 1 <sup>st</sup> month (ng/ml)	Dose 1 <sup>st</sup> month (mg/kg/ day)	L/D 1 <sup>st</sup> month (ng/ml/ mg/kg/ day)	Level 3 <sup>rd</sup> month (ng/ml)	Dose 3 <sup>rd</sup> month (mg/kg/ day)	L/D 3 <sup>rd</sup> month (ng/ml/ mg/kg/ day)	Level 6 <sup>th</sup> month (ng/ml)	Dose 6 <sup>th</sup> month (mg/kg/ day)	L/D 6 <sup>th</sup> month (ng/ml/ mg/kg/ day)
Donors									
CYP3A5*3/*3(n=27)	8.07 ±3.52	0.081 ±0.041	114.92 ±61.77	8.15 ±3.23	0.057 ±0.030	196.15 ±176.39	7.63 ±2.36	0.0449 ±0.025	251.1 ±233.9
*1/*3(n=5)	6.51 ±2.17	0.097 ±0.044	71.86 ±18.83	8.45 ±2.23	0.111* ±0.057	88.46 ±38.25	6.79 ±1.51	0.086* ±0.051	95.44* ±37.47
Recipients									
CYP3A5*3/*3(N=29)	7.67 ±3.31	0.081 ±0.041	109.54 ±60.59	8.33 ±3.19	0.061 ±0.029	186.61 ±171.82	7.45 ±2.3	0.0473 ±0.024	232.31 ±228.74
*1/*3(N=2)	10.71 ±4.96	0.127 ±0.042	96.22 ±71.24	6.78 ±1.01	0.118 ±0.129	130.25 ±133.7	7.68 ±2.80	0.102 ±0.106	194.95 ±230.16
*1/*1(n=1)	6.60	0.071	92.95	7.14	0.108	66.1	8.57	0.066	129.8
*1/*3+*1/*1(n=3)	9.34 ±4.23	0.108 ±0.044	95.13 ±50.41	6.90 ±0.74	0.115 ±0.091	108.87 ±101.54	7.97 ±2.04	0.09 ±0.078	173.23 ±167.04
Donors									
ABCB1 Ex-21GG (n=23)	8.16 ±3.50	0.088 ±0.046	110.35 ±65.66	8.11 ±3.36	0.064 ±0.045	201.14 ±192.87	7.46 ±2.55	0.049 ±0.038	257.78 ±254.85
GT (n=7)	7.23 ±3.33	0.069 ±0.024	109.28 ±44.2	8.31 ±2.41	0.068 ±0.024	127.12 ±29.21	7.31 ±1.40	0.050 ±0.014	156.73 ±57.93
TT (n=2)	6.12 ±2.08	0.076 ±0.015	79.45 ±11.24	8.80 ±2.54	0.079 ±0.001	111.1 ±30.26	8.6 ±0.42	0.0745 ±0.0007	115.38 ±4.55
GT+TT(n=9)	6.98 ±3.01	0.070 ±0.021	102.65 ±40.67	8.42 ±2.28	0.070 ±0.021	123.56 ±28.36	7.59 ±1.35	0.055 ±0.016	147.54 ±53.4
Recipients									
ABCB1 Ex-21GG (n=27)	8.03 ±3.46	0.084 ±0.043	110.95 ±60.09	8.13 ±3.09	0.064 ±0.041	189.38 ±178.81	7.55 ±2.32	0.05 ±0.03	240.78 ±238.14
GT (n=5)	6.72 ±2.86	0.079 ±0.030	93.29 ±57.54	8.57 ±3.27	0.077 ±0.033	125.04 ±61.16	7.19 ±2.06	0.058 ±0.032	151.12 ±73.87
Donors									
ABCB1 Ex-26CC (n=10)	7.88 ±3.50	0.075 ±0.032	112.55 ±43.71	7.41 ±1.82	0.063 ±0.031	176.68 ±190.47	8.13 ±2.03	0.053 ±0.026	245 ±290.46
CT (n=15)	6.88 ±2.61	0.081 ±0.035	103.86 ±75.19	8.26 ±2.55	0.071 ±0.048	162 ±110.2	7.35 ±2.15	0.055 ±0.040	186.63 ±103.45
TT (n=7)	9.77 ±4.18	0.101 ±0.060	111.24 ±43.88	9.21 ±5.12	0.059 ±0.034	220.2 ±241.38	6.90 ±2.84	0.039 ±0.0235	288.75 ±307.81
CT+TT(n=22)	7.80 ±3.38	0.087 ±0.045	106.21 ±65.82	8.56 ±3.47	0.067 ±0.043	180.53 ±159.93	7.21 ±2.33	0.05 ±0.036	218.49 ±191
Recipients									
ABCB1 Ex-26CC (n=5)	6.72 ±2.86	0.079 ±0.030	93.29 ±57.54	8.57 ±3.27	0.077 ±0.033	125.04 ±61.16	7.19 ±2.06	0.058 ±0.032	151.12 ±73.87
CT (n=19)	8.07 ±3.21	0.078 ±0.035	121.54 ±64.38	8.47 ±3.28	0.063 ±0.045	216.46 ±205.76	8.17 ±2.34	0.051 ±0.038	274.95 ±274.51
TT (n=8)	7.93 ±4.22	0.099 ±0.059	85.78 ±41.53	7.33 ±2.60	0.065 ±0.029	125.06 ±56.28	6.09 ±1.53	0.046 ±0.022	159.63 ±78.64
CT+TT(n=27)	8.03 ±3.46	0.084 ±0.043	110.95 ±60.09	8.13 ±3.09	0.064 ±0.041	189.38 ±178.81	7.55 ±2.32	0.05 ±0.03	240.78 ±238.14

\* statistically significant values (P&lt;0.05, Mann-Whitney U-test).

the \*3 allele and this in absence of significant variations of tacrolimus  $C_0$  levels between the two groups. A similar, but statistically non-significant, trend was observed also one month after transplantation (Table 2); it can be seen that at that time the tacrolimus  $C_0$  levels were substantially lower in the patients receiving livers with \*1/\*3 ( $6.51 \pm 2.17$  ng/mL) rather than with \*3/\*3 ( $8.07 \pm 3.52$  ng/mL), thus possibly hindering a stronger effect of the donors' genotype on tacrolimus dose requirements.

Also for the recipients' genotypes, the presence of at least one \*1 copy tended to increase tacrolimus doses and to lower dose-adjusted  $C_0$ , though the differences with respect to the \*3/\*3 genotypes were not statistically significant in any of the time intervals considered (Table 2). The data of Table 2 also show that there were no significant influences of the *ABCB1* 2677G>T or 3435C>T SNPs, present either in the donors' or in the recipients' genotypes, on tacrolimus dosing requirements during the first six months after transplantation.

This was seen also when the possible effects of the same *ABCB1* SNPs were analysed taking into account the presence or not of the \*1 CYP3A5 allele in the donors' or in the recipients' genotypes (not shown).

Finally, also according to previous reports [30–34], tacrolimus dosing requirements were not different according to the sex of either the donors or of the recipients (not shown). It is debated whether co-exposure to steroids may influence tacrolimus clearance at CYP3A level [35–37]; however, in this series we did not find any significant differences in the tacrolimus dosages needed by the patients receiving steroids with respect to those steroid-free (analysis not shown), also when the different genotypes of the recipients and of the donors were considered. This may depend on the fact that steroids, according to the patient's clinical condition and in the absence of rejection, were rapidly tapered and then discontinued during the first month after transplantation [5,33].

## DISCUSSION

Analysis of *CYP3A5* and *ABCB1* SNPs revealed a high overall percentage of homozygosity for the CYP3A5\*3 variant (6986A>G at intron 3) in the present population composed entirely of Caucasian subjects. This result is in good agreement with other reports which have indicated

that up to 90% of Caucasians have such genotype [10,38–40]; in other races, in particular in Africans or African-Americans, the percentage of subjects with the \*3/\*3 genotype is much lower (about 30%) [10,38,40,41]. As for the *ABCB1* SNP 2677G>T at exon 21, we observed a total frequency of the allelic variant T (12.5%) lower than that (40–50%) observed in other Caucasian populations [28,42–44] and more similar to that (13%) of African-American individuals [27,29,44]. This finding might perhaps represent a peculiarity of our population mainly made up of Sicilians; however the difference in the frequencies of T between Sicilians (9%,  $n=50$ ) and non-Sicilians (25%,  $n=14$ ) was not statistically significant.

As for the *ABCB1* 3435C>T SNP at exon 26, the overall frequency of the allelic variant T was 50%, in accordance with other studies which have reported percentages in Caucasians between 33% and 65% [42,44,45]. In our population there was not the linkage between the 2677G>T and 3435C>T SNPs suggested by other authors [21,44,46].

Considering the relationship between genotypes and tacrolimus dose requirements, it has been shown that subjects homozygous for the \*3 variant do not express functional CYP3A5 and exhibit lower clearance of the drug [11,29,47,48]. For this reason, they require lower doses of tacrolimus to reach target blood levels compared with the subjects with at least one \*1 allele (expressors). Results of this kind have been found checking the genotypes of kidney, heart and lung transplanted patients [13,49–51]. As for liver transplants, our data confirm those of other authors who have indicated the main importance of the liver donors' genotype with regard to the expression of CYP3A5 [52]. They trend to suggest also some influence of the recipients' genotype, implying the possible role that CYP3A5 may play also in extrahepatic tissues like the intestinal wall, as others have reported [53].

With regard to *ABCB1* SNPs, previous studies have not produced consistent results: some authors have indicated that the subjects homozygous for the variant allele 3435T at exon 26 present a reduction in intestinal P-gp, with an effect on the bioavailability of P-gp substrates like cyclosporine and tacrolimus [19,21,24,50,54]. Nevertheless, several other studies performed in kidney, lung and heart transplant patients have excluded that *ABCB1* genetic polymorphisms play any relevant role in determining cyclosporine or tacrolimus

pharmacokinetics [14,25,55–59]. Though our present data need to be corroborated in a larger population of patients, they are in agreement with the latter conclusion, since there were no significant influences of the *ABCB1* 2677G>T or 3435C>T SNPs, present in the recipients' or also in the donors' genotypes, on tacrolimus dosing requirements during the first six months after transplantation.

Finally, we observed a very wide variability of the tacrolimus doses required to reach target blood levels even among the patients carrying the same genotype (in particular of *CYP3A5*, whose SNP appeared to be functionally active) and with a high overlap of the values between the wild-type and mutant genotypes. This further underlines that genetic polymorphism is only one of the possible factors which may influence tacrolimus pharmacokinetics [34,60–62].

## CONCLUSIONS

The results of the present study suggest that pharmacogenetic analysis cannot substitute therapeutic drug monitoring, even though genotyping the *CYP3A5*\*3 polymorphism of the donor can represent a useful tool to evaluate the appropriate initial dosage of tacrolimus in liver transplant patients.

## REFERENCES:

- Venkataraman R, Swaminatan A, Prasad T et al: Clinical pharmacokinetics of tacrolimus. *Clin Pharmacokinet*, 1995; 29: 404–30
- Ihara H, Shinkuma D, Ichikawa Y et al: Intra-and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. *Int J Urol*, 1995; 2: 151–55
- Jusko WJ: Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. *Ther Drug Monit*, 1995; 17: 596–601
- Lampen A, Christians U, Guengerich FP et al: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. *Drug Metab Dispos*, 1995; 23: 1315–24
- Staatz CE, Willis C, Taylor PJ et al: Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. *Liver Transp*, 2003; 9: 130–37
- Kalow W, Tang BK, Endrenyi L: Hypothesis. Comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics*, 1998; 8: 283–89
- Sattler M, Guengerich FP, Yun CH et al: Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. *Drug Metab Dispos*, 1992; 20: 753–61
- Thummel KE, Wilkinson GR: *In vitro* and *in vivo* drug interactions involving human CYP3A. *Annu Rev Pharmacol Toxicol*, 1998; 38: 389–430
- Cholerton S, Daly AK, Idle JR: The role of individual human cytochrome P450 in drug metabolism and clinical response. *Trends Pharmacol Sci*, 1992; 13: 434–39
- Kuehl P, Zhang J, Lin Y et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet*, 2001; 27: 383–91
- Goto M, Masuda S, Kiuchi T et al: CYP3A5\*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. *Pharmacogenetics*, 2004; 14: 471–78
- Macphee I, Fredericks S, Tai T et al: Tacrolimus pharmacogenetics. Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. *Transplantation*, 2002; 74: 1486–89
- Zheng H, Zeevi A, Schuetz E et al: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. *J Clin Pharmacol*, 2004; 44: 135–40
- Tsuchiya N, Satoh S, Tada H et al: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. *Transplantation*, 2004; 78: 1182–87
- Saeki T, Ueda K, Tanigawara Y et al: Human P-glycoprotein transports cyclosporin A and FK506. *J Biol Chem*, 1993; 268: 6077–80
- Thiebaut F, Tsuruo T, Hamada H et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue. *Proc Natl Acad Sci USA*, 1987; 84: 7735–38
- Hall SD, Thumel KE, Watkins PB et al: Molecular and physical mechanisms of first-pass extraction. *Drug Metabol Dispos*, 1999; 27: 161–66
- Zhang Y, Benet LZ: The gut as a barrier to drug absorption. Combined role of cytochrome P450 3A and P-glycoprotein. *Clin Pharmacokinet*, 2001; 40: 159–68
- Hoffmeyer S, Burk O, von Richter O et al: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity *in vivo*. *Proc Natl Acad Sci USA*, 2000; 97: 3473–78

20. Siegmund W, Ludwig K, Giessmann T et al: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. *Clin Pharmacol Ther*, 2002; 72: 572–83
21. Anglicheau D, Verstuyft C, Laurent-Puig P et al: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. *J Am Soc Nephrol*, 2003; 14: 1889–96
22. Wang D, Johnson AD, Papp AC et al: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. *Pharmacogenet Genomics*, 2005; 15: 693–704
23. Fredericks S, Moreton M, Reboux S et al: Multi-drug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. *Transplantation* 2006; 82: 705–8
24. Li D, Gui R, Huanz Z, Nie X: Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. *Transplant Proc*, 2006; 38: 2580–82
25. von Ahsen N, Richter M, Grupp C et al: No influence of the MDR-1 C3435T polymorphisms or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentration or rejection incidence in stable renal transplant recipients. *Clin Chem*, 2001; 47: 1048–52
26. Min DI, Ellingrod VL: C3435T mutation in exon 26 of the human MDR-1 gene and cyclosporine pharmacokinetics in healthy subjects. *Ther Drug Monit*, 2002; 24: 400–4
27. Jeannesson E, Albertini L, Siest G et al: Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. *Fundam Clin Pharmacol*, 2007; 21: 411–18
28. Cascorbi I, Gerloff T, Johne A et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. *Clin Pharm Ther*, 2001; 69: 169–74
29. Utecht KN, Hiles JJ, Kolesar J: Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. *Am J Health Syst Pharm*, 2006; 63: 2340–48
30. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther*, 1994; 270: 414–23
31. Schmucker DL, Woodhouse KW, Wang RK et al: Effects of age and gender on *in vitro* properties of human liver microsomal monooxygenases. *Clin Pharmacol Ther*, 1990; 48: 365–74
32. George J, Byth K, Farrell GC: Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. *Biochem Pharmacol*, 1995; 50: 727–30
33. Lee JY, Hahn HJ, Son IJ et al: Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. *Pharmacotherapy*, 2006; 26: 1069–77
34. Cotreau MM, Von Moltke LL and Greenblatt DJ: The influence of age and sex on the clearance of cytochrome P450A3 substrates. *Clin Pharmacokinet*, 2005; 44: 33–60
35. Mourad M, Mourad G, Wallemacq P et al: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. *Transplantation*, 2005; 80: 977–84
36. Anglicheau D, Flamant M, Schlageter MH et al: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. *Nephrol Dial Transplant*, 2003; 18: 2409–14
37. Shimada T, Terada A, Yokogawa K et al: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. *Transplantation*, 2002; 74: 1419–24
38. Lamba JK, Lin YS, Shuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev*, 2002; 54: 1271–94
39. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. *Clin Chem*, 2002; 48: 1668–71
40. Hustert E, Haberl M, Burk O et al: The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics*, 2001; 11: 773–79
41. Dirks NL, Huth B, Yates CR, Meibohm B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. *Int J Clin Pharmacol Ther*, 2004; 42: 701–18
42. Ifergan I, Bernard NF, Bruneau J et al: Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. *AIDS*, 2002; 16: 2340–42
43. Cavaco I, Gil JP, Gil-Berglund E and Ribeiro V: CYP3A4 and MDR1 alleles in a Portuguese population. *Clin Chem Lab*, 2003; 41: 1345–50
44. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among Europeans Americans and African Americans. *Clin Pharmacol Ther*, 2001; 70: 189–99
45. Ameyaw MM, Regateiro F, Li T et al: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. *Pharmacogenetics*, 2001; 11: 217–21.

46. Wang J, Zeevi A, McCurry K et al: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing adult lung transplant patients who are CYP3A5\*3/\*3 non-expressors. *Transplant Immunology*, 2006; 15: 235-40
47. Dai Y, Hebert MF, Isoherranen N et al: Effects of CYP3A5 polymorphism on tacrolimus metabolic clearance *in vitro*. *Drug Metab Dispos*, 2007; 34: 836-47
48. Li D, Lu W, Zhu JY et al: Population pharmacokinetics of tacrolimus and CYP3A5, MDR-1 and IL-10 polymorphisms in adult liver transplant patients. *J Clin Pharm Ther*, 2007; 32: 505-15
49. Thervet E, Anglicheau D, King B et al: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to dose ratio in renal transplant recipients. *Transplantation*, 2003; 76: 1233-35
50. Zheng H, Webber S, Zeevi A et al: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. *Am J Transplant*, 2003; 3: 477-83
51. MacPhee IA, Fredericks S, Tai T et al: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. *Am J Transplant*, 2004; 4: 914-19
52. Yu S, Wu L, Jin J et al: Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. *Transplantation*, 2006; 81: 46-51
53. Uesugi M, Masuda S, Katsura T et al: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. *Pharmacogenet Genomics*, 2006; 16: 119-27
54. Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. *Pharmacogenomics*, 2003; 4: 397-410
55. Haufroid V, Mourad M, Van Kerckhove V et al: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenetics*, 2004; 14: 147-54
56. Fredericks S, Jorga A, MacPhee IA et al: Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5\*1 genotype have no influence on cyclosporine dose requirements as assessed by C<sub>0</sub> or C<sub>2</sub> measurements. *Clin Transplant*, 2007; 21: 252-57
57. Mai I, Perloff ES, Bauer S et al: MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. *Br J Clin Pharmacol*, 2004; 58: 548-53
58. Op den Buijsch RA, Christiaans MH, Stolk LM et al: Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. *Fundam Clin Pharmacol*, 2007; 21: 427-35
59. Tada H, Tsuchiya N, Satoh H: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. *Transplant Proc*, 2005; 37: 1730-32
60. Zahir H, McLachlan AJ, Nelson A et al: Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. *Ther Drug Monit*, 2005; 27: 422-30
61. Christians U, Strom T, Zhang YL et al: Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. *Ther Drug Monit*, 2006; 28: 39-44
62. Burckart GJ and Liu XI. Pharmacogenetics in transplant patients. Can it predict pharmacokinetics and pharmacodynamics? *Ther Drug Monit*, 2006; 28: 23-30